Fluoroquinolone於結核病治療的角色

The Role of Fluoroquinolone in Tuberculosis

楊淑珍(Shu-Chen Yang) ； 陳家豪(Chia-Hao Chen) ； 鄭高珍(Kuo-Chen Cheng) ； 陳麗芳(Agnes L. F. Chan)

《內科學誌》 21卷1期 (2010/02) Pp. 32-41

https://doi.org/10.6314/JIMT.2010.21(1).05

摘要

隨著研究的發展，fluoroquinolone的選擇於結核治療指引有所不同。經過活性結構的修飾，新一代fluoroquinolone展現卓越的抗結核效果；本文藉由探討fluoroquinolone的結構相關特性與藥物動力學表現，並參照臨床使用fluoroquinolone於結核治療的試驗結果，逐一比較不同世代的fluoroquinolone如ofloxacin、ciprofloxacin、levofloxacin、moxifloxacin、gatifloxacin及sparfloxacin在長期結核病治療的有效性與安全性。最後彙整治療指引，再次檢視fluoroquinolone於結核治療的角色、使用時機與相關應注意的事項，希望提供臨床選擇使用fluoroquinolone之參考依據。

關鍵字

Fluoroquinolone ； 結核菌 ； 有效性 ； 安全性

並列摘要

Fluoroquinolones are used to treat tuberculosis based on in vitro and clinical studies. Recently, WHO recommened later-generation of fluoroquinolones, levofloxacin and moxifloxacin rather than ciprofloxacin as antituberculosis in the management of patients with ofloxacin resistance. Studies showing the different potency between older and newer-generation of fluoroquinolones in vitro and in vivo are discussed in this article. Besides, optimal policy was referred according to the pharmacodynamic properties of fluoroquinolones and the guidelines of antituberculosis. We evaluated the efficacy, susceptibility, pharmacodynamics and safety concern as clinical factors to choose the most appropriate fluoroquinolone for antituberculosis.

並列關鍵字

Fluoroquinolone ； Tuberculosis ； Efficacy ； Safety